Thursday, July 28, 2022 8:54:02 AM
Change Text Size:
Default text sizeA Larger text sizeA Largest text sizeA
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
BY GlobeNewswire
— 7:00 AM ET 07/28/2022
Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM) , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2022 on Tuesday, August 9, 2022 before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 AM Eastern Time on August 9, 2022 to discuss these results and provide a business update.
To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. A recording of the conference call will be available on the Company’s website for approximately 30 days following the live event.
DISCLAIMER: All I say is just IMHO and does not constitute investment advice. My wife informs me frequently that I know nothing. I say you should trust no one on the internet.
Recent AXSM News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 11:05:55 AM
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc. • GlobeNewswire Inc. • 08/21/2024 11:00:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:27:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 09:07:28 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/05/2024 08:36:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:05:45 AM
- Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/05/2024 11:00:00 AM
- U.S. Index Futures and Oil Prices Plunge on Recession Concerns • IH Market News • 08/05/2024 09:46:20 AM
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5 • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:31:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:38:42 AM
- Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories • GlobeNewswire Inc. • 06/05/2024 11:35:00 AM
- Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:12:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 12:11:32 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:24:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 08:23:38 PM
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 • GlobeNewswire Inc. • 05/29/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:28:52 PM
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting • GlobeNewswire Inc. • 05/28/2024 11:00:00 AM
- Axsome Therapeutics to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
FEATURED Element79 Gold Corp Provides Update on Nevada Portfolio • Aug 23, 2024 8:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM